Please Note: This trial is no longer enrolling new participants
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
| Protocol No. | CTO-A011801 | Scope | National |
|---|---|---|---|
| Principal Investigator | Kathy Miller | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
